亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

作者
Alexander M. Lesokhin,Joshua Ryan Richter,Suzanne Trudel,Adam D. Cohen,Andrew G Spencer,Peter A. Forsberg,Jacob P. Laubach,Sheeba K. Thomas,Nizar Jacques Bahlis,Luciano J. Costa,Paula Rodríguez‐Otero,María‐Victoria Mateos,Jesús G. Berdeja,Rayan Kaedbey,Amrita Y. Krishnan,Rafaël Fonseca,Voleak Choeurng,James Fenimore Cooper,Teiko Sumiyoshi,Chihunt Wong
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 4415-4417 被引量:80
标识
DOI:10.1182/blood-2022-157547
摘要

Background: Relapsed/refractory multiple myeloma (RRMM) remains an incurable disease, with most treatment regimens continued until disease progression (PD). New treatments that are efficacious when given for a fixed duration and offer the potential for an extended treatment-free period may also decrease cumulative toxicities and reduce the burden of treatment on both patients and healthcare systems. Cevostamab is an FcRH5xCD3 T-cell engaging bispecific monoclonal antibody that facilitates T-cell directed killing of myeloma cells and has demonstrated clinically meaningful activity and a favorable toxicity profile when given Q3W for up to 17 cycles (approximately 1 year) in an ongoing Phase I trial (GO39775; NCT03275103) in patients with heavily pre-treated RRMM (Trudel et al. ASH 2021). Here, we report early duration of response data for patients in GO39775 who completed 17 cycles of cevostamab and stopped treatment. Methods: All patients were aged ≥18 years and had RRMM for which no established therapy was available, appropriate, or tolerable, and an ECOG performance status of 0-1. Cevostamab was administered by intravenous infusion in 21-day cycles with step-up dosing in Cycle (C) 1 for cytokine release syndrome mitigation. Treatment was continued for 17 cycles (approximately 1 year) unless PD or unacceptable toxicity occurred. Patients who achieved a partial response (PR) or better by C17 and maintained a response through C17 were included in the analysis. Results: At data cut-off (March 8, 2022), a total of 16 patients (median age: 66.5 years; range: 45-80) completed C17 of cevostamab treatment and were eligible for analysis. Patients had received a median of 6 prior lines of therapy (range: 2-11), with 12 patients having received ≥5 prior therapies. Thirteen patients were triple-class refractory and 11 were penta-refractory. Fifteen patients were refractory to their last prior therapy. Five patients had received prior anti-B-cell maturation antigen (BCMA) targeted therapies, 4 of whom were refractory to anti-BCMA treatment. Patients received cevostamab target doses ranging from 40-160mg and received a median of 17 cycles of treatment (range: 16-17). Among the 16 patients analyzed, the best overall response (BOR) achieved was: stringent complete response (sCR) in 7 patients, CR in 3 patients, very good partial response (VGPR) in 5 patients, and PR in 1 patient. At data cut-off, 13 of the 16 patients remained in remission, with 8 patients (BOR: 5 sCR, 1 CR, 2 VGPR) maintaining a response ≥6 months after completion of therapy and 3 patients (BOR: 2 sCR, 1 CR) maintaining a response ≥12 months after completion of therapy. Eight patients had <6 months of follow-up. None of the patients (0/10) who completed C17 and attained a sCR or CR had relapsed. Only 3 of the 16 patients (BOR: 2 VGPR, 1 PR) had PD after the completion of C17 of cevostamab. Time to progression following completion of therapy for the 2 patients who achieved a VGPR was 7.8 months and 12.9 months. For the patient who achieved a PR, time to progression was 1.3 months. Due to its mechanism of action, treatment with cevostamab may be associated with an increased risk of infection. Infections occurred in 2 patients after the completion of C17 of cevostamab therapy. Pneumonia was reported in both patients, with onset after the last dose of 1.3 months and 3.8 months. Both events resolved and both patients have remained on study. Conclusions: Early data from this Phase I study suggest that patients can maintain durable responses (≥6 months) after completion of 17 cycles of cevostamab treatment, highlighting the potential for an extended treatment-free period following fixed-duration therapy. Further data are needed to confirm the duration of response and associated correlates following completion of treatment. Additional data on responding patients with premature discontinuation of treatment (i.e. prior to completion of C17) and patients retreated with cevostamab will be presented.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
纯情的阁发布了新的文献求助10
5秒前
13秒前
深情的从丹完成签到,获得积分10
17秒前
21秒前
阿丕啊呸完成签到,获得积分10
26秒前
29秒前
30秒前
null的应助被伊比利亚的微风采纳,获得10
31秒前
认真的笑卉完成签到,获得积分10
32秒前
40秒前
aba发布了新的文献求助10
46秒前
hamburger完成签到,获得积分10
49秒前
null的应助被等待若魔采纳,获得10
54秒前
陶醉成协完成签到,获得积分10
56秒前
haralee完成签到 ,获得积分10
1分钟前
1分钟前
乐正元正完成签到,获得积分10
1分钟前
时尚的蜜蜂完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
1分钟前
Logan1001发布了新的文献求助10
1分钟前
1分钟前
1分钟前
bkagyin的应助被Logan1001采纳,获得10
1分钟前
hyman发布了新的文献求助10
1分钟前
1分钟前
1分钟前
生动琦完成签到,获得积分10
1分钟前
彩色的可冥完成签到,获得积分10
1分钟前
Logan1001完成签到,获得积分20
2分钟前
2分钟前
从容煜城完成签到,获得积分10
2分钟前
2分钟前
顺利秋天完成签到,获得积分10
2分钟前
甜甜的黑猫完成签到,获得积分10
2分钟前
3分钟前
等待若魔完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354